CD4+ T lymphocyte bearing neoantigen-specific T-cell receptor (Neo-TCR CD4+ T cell) (Neo-TCR CD4+ T cell)

CD4+ T lymphocytes bearing neoantigen-specific T-cell receptors (TCRs) are a specialized subset of immune cells that recognize unique, tumor-specific mutations presented by Major Histocompatibility Complex (MHC) Class II molecules (Tran et al., 2014, Science). Unlike traditional T cells that target conserved self-antigens, these cells are primed against "neoantigens" resulting from somatic mutations in the cancer genome, making them highly specific to the tumor and minimizing the risk of systemic autoimmunity (Ott et al., 2017, Nature). Their primary biological function involves the orchestration of the immune response through the secretion of pro-inflammatory cytokines like interferon-gamma and tumor necrosis factor, which enhance the activity of CD8+ cytotoxic T cells and modify the tumor microenvironment (Alspach et al., 2019, Nature). In the context of oncology, these cells are central to the efficacy of personalized cancer vaccines and adoptive cell transfer (ACT) therapies (Sahin et al., 2017, Nature). Therapeutic strategies aim to either expand these cells ex vivo for re-infusion or induce their proliferation in vivo using neoantigen-based vaccines. Monitoring the frequency and activation state of these cells serves as a critical biomarker for treatment response in patients receiving immune checkpoint inhibitors or personalized immunotherapies. These cells are increasingly recognized for their direct cytotoxic potential against MHC Class II-positive tumor cells, further expanding their role in cancer eradication. The specificity of their TCRs ensures that the immune attack is confined to malignant tissue, addressing a major challenge in conventional chemotherapy and non-specific immunotherapy.

Other names

Neoantigen-specific CD4+ T cellsMutation-specific CD4+ T cellsMHC class II-restricted neoantigen-specific T cellsNeo-TCR CD4+ T lymphocytes

Recognition of tumor-specific neoepitopes presented on MHC Class II molecules leading to T-cell activation, cytokine secretion (IFN-gamma, TNF-alpha), and orchestration of a multi-pronged anti-tumor immune response (Alspach et al., 2019, Nature).